Global Life Sciences BPO Market Future Developments, Business Insights, End Users, Application And Forecast To 2024 Appraised By Global Players Anthelio Healthcare Solutions, Accenture plc, Cognizant Technology Solutions, Catalent, Inc.

Life science business process outsourcing (BPO) is one of the most lucrative industries in the healthcare sector. Constantly rising pricing pressure and increasing competition is compelling pharmaceutical and medical device companies to strategically reduce their operational costs and in turn benefit from higher profits. This has led to an increasing demand for contract manufacturing outsourcing (CMO) and contract research outsourcing (CRO) services. Asia and Latin America are the most attractive markets for CMO and CRO, owing to low costs of production and research activities performed here.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/24

Market Dynamics

The global life sciences BPO market is driven by factors such as increasing cost of research and development (R&D), growing price pressures, and increase in investments by pharmaceutical and medical devices companies in emerging economies such as India, China, Brazil, and South Africa. Pharmaceutical and medical device companies are adopting inorganic growth strategies to expand their business and reduce their Capital Expenditure (CAPEX) and Operation Costs (OPEX). However, outsourcing certain services to different CMO and CRO companies located in other countries is a challenge for the outsourcing company to monitor and follow a particular set of guideline for product approval pertaining to regulatory filings, clinical trials and medical writing. Collaborative efforts among various stakeholders of the ecosystem is analyzed to benefit the life science BPO industry in the long run.

Key companies covered as a part of this study include Anthelio Healthcare Solutions, Accenture plc, Cognizant Technology Solutions, Catalent, Inc., Covance, Inc., Boehringer Ingelheim GmbH, Genpact Limited, Lonza Group, PAREXEL International Corporation and Quintiles Transnational Corporation.

Detailed Segmentation:

Global Life Sciences BPO Market, By Service Type:
Medical Device Outsourcing
Pharmaceutical Outsourcing
CMO
API Manufacturing
Final dosage form manufacturing
Packaging
CRO
Drug Discovery
Preclinical studies
Early Phase I - IIa
Phase IIa - III
Phase IIIb - IV
Medical coding and writing
Monitoring
Clinical Data Management
Bio-statistics
Site management
Protocol development
Regulatory Information

Global Life Sciences BPO Market, By End User:
Healthcare Providers
Healthcare Payers

Global Life Sciences BPO Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Patent Expirations To Boost The Prospects For Life Sciences Bpo Market

According to UBM India Pharma Publication, over US$ 40 billion worth of drug are expected to be off-patent in the U.S. by 2017. Also, in 2014, utilization of generic drugs resulted in savings of around US$ 254 billion in the U.S. This trend is anticipated to increase further with more patent expirations in the near future. This factor coupled with the advent of biosimilars is projected to favor the growth of life sciences BPO market over the forecast period.

India Home To Second-Highest Number Of U.S. Fda Approved Manufacturing Facilities, An Attractive Proposition For India’S Life Sciences Bpo Market

Demand for contract manufacturing and contract research services in Asia is high, mainly due to large number of FDA approved drug manufacturing plants in this region. According to the UBM India Pharma Publication report of 2015, Indian accounts for 22% of the overall U.S. FDA approved drug manufacturing facilities globally. Moreover, dynamics such as wide availability of highly trained professionals, cheap labor, large patient pool, and easy availability of subjects for clinical trials are positioning Asia Pacific as a major life sciences BPO market. The life sciences BPO market in this region is expected to expand at a CAGR of 16.6% during the forecast period.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/24

Uncertainty And Differences In Government Regulations To Increase Demand For Regulatory Outsourcing Services

Healthcare companies are subject to highly uncertain regulations that change according to country and changing government priorities. For instance, Section 3d of the Indian Pharma Act does not approve any new drug that is an altered form of a known molecule and not representing an improved efficacy over the existing molecule. While this drug is approved in the U.S., U.K, Australia and other countries. Dismissal of such patent applications discourages investment in countries with high growth potential. Also, mandatory licensing and patent ever-greening strategies further makes regulatory filing in a country more complex. Hence, healthcare companies hire regulatory experts of the respective countries to execute the regulatory process smoothly in that particular country.

Import and distribution of drug or medical devices in several countries require regulatory clearance that is efficiently managed by life science BPO companies. This enables pharmaceutical, biotech and medical device companies to focus on their core activities such as research, marketing, distribution agreements, and increasing product availability. The regulatory information segment is expected to grow swiftly to reach US$ 35 billion by 2024, on account of increasing abbreviated new drug application (ANDA) filings and growing interest in biosimilars.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.